Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Medicenna Granted U.S. Patent Number 11,680,090 Titled 'Interleukin-2 Fusion Proteins and Uses Thereof'

Author: Benzinga Newsdesk | August 01, 2023 09:33am

Medicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 titled "Interleukin-2 Fusion Proteins and Uses Thereof."
The patent covers a method for enhancing immune cell survival and proliferation or inhibiting cell death and therefore improving fitness of cancer fighting immune cells.

Posted In: MDNA